Companies /Healthcare

Omeros Corporation

NASDAQ: OMER Biotechnology
$16.68
▼ $0.81 (−4.63%) today
Markets closed · 8:41pm ET

OMER at a Glance

Valuation
Market cap
$1.3B
P/E ratio
14.3
Profitability
Revenue (TTM)
$38.4M
Profit margin
324.9%
EPS (TTM)
$1.22
Price
52-week range
$7 – $21
Street target
$27.50

Headquartered in Seattle, WA Fiscal year ends December NASDAQ: OMER omeros.com

About Omeros

Omeros Corporation is a commercial-stage biotechnology company that discovers, develops and commercializes first-in-class protein and small-molecule therapeutics. It focuses on complement-mediated diseases, cancers, and addictive or compulsive disorders.

Its marketed product is YARTEMLEA (narsoplimab-wuug), a MASP-2 inhibitor targeting the lectin pathway. YARTEMLEA is FDA-approved and sold in the U.S. for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and in children two years of age and older. The product benefits from Medicare NTAP inpatient reimbursement effective October 1, 2026. The European CHMP issued a negative opinion on its marketing application in 2026.

Omeros plans to expand YARTEMLEA into other endothelial-injury indications, including ARDS and TA-TMA prevention. Its pipeline includes:
- OMS1029, a long-acting MASP-2 antibody that has completed Phase 1;
- oral MASP-2 and MASP-3 small-molecule programs;
- OMS527, a PDE7 inhibitor for cocaine use disorder, funded by NIDA;
- OncotoX-AML/OMS805, targeting acute myeloid leukemia;
- the T-CAT recombinant antibody platform, targeting multidrug-resistant infections.

Novo acquired global rights to the MASP-3 inhibitor zaltenibart in 2025. Omeros remains eligible for more than $1.8 billion in milestones plus tiered royalties. The company also carries an OMIDRIA contract royalty asset and related royalty obligation, along with convertible 2029 Notes. Updated

Latest Activity

OMEROmeros
Q3 2026
EPS
$0.06
est -$0.02+$0.08
Revenue
$36M
est $37M-3.6%

Omeros turned a profit a quarter ahead of what analysts modeled, yet traders sold anyway after revenue came in missing the $37.3 million consensus. YARTEMLEA net product revenue still rose 26% sequentially, with Medicare NTAP payments live since October 1.

Quarterly EPS — reported vs estimate

OMER Coverage

Frequently Asked Questions

What does Omeros do?

Omeros Corporation is a commercial-stage biotechnology company that discovers, develops and commercializes first-in-class protein and small-molecule therapeutics. It focuses on complement-mediated diseases, cancers, and addictive or compulsive disorders.

What is the OMER stock price target?

The Wall Street consensus 12-month price target for OMER is $27.50.